Navigation Links
Musculoskeletal Network Launches Special Coverage of FDA Biosimilars Policy
Date:11/16/2012

NORWALK, Conn., Nov. 16, 2012 /PRNewswire/ -- UBM Medica US announces that MusculoskeletalNetwork features special coverage of sessions from the annual meeting of the  American College of Rheumatology (ACR), including the latest information about new FDA processes for approval of biosimilars that are like generic versions of expensive medications now used to treat painful rheumatologic conditions such as rheumatoid arthritis (RA).

Many newer "biological" drugs currently approved for these disorders, such as adalimumab (Humira) and rituximab (Rituxan), are identical to molecules created by the human immune system, except that these drugs are manufactured in cell cultures by bioengineering processes. Their high cost, which can run into the tens of thousands of dollars per month, should drop if manufacturers are allowed to sell identical "follow-on" products once the patent on the original drugs expires, just as less-expensive generic versions of other drugs are now on the market. Since the biosimilars would not be produced in exactly the same kinds of cells, there are concerns that they might not be as safe or effective as the original biological.

As part of the Affordable Care Act, the US Congress passed legislation in 2010 authorizing the FDA to establish policies to regulate biosimilars. In the article "FDA Panel on Biosimilars: Analytics Should Trump Clinical Trials" Musculoskeletal Network cites FDA officials at the ACR conference speaking to the specific concerns of rheumatologists attending the conference. These specialists are particularly interested in the issue as these drugs, used at first primarily to treat cancer, are now proving effective for many rheumatologic disorders such as lupus and forms of arthritis.

Also reporting from the conference, Musculoskeletal Network reveals promising results of pre-approval studies on prospective drugs for RA, which may be safer and more effective than the first oral medication for this condition, tofacitinib (Xeljanz). Tofacitinib was approved by the FDA only last week.

About UBM Medica US

Addressing today's healthcare information needs, UBM Medica US, delivers strategic, integrated communications solutions and comprehensive reach—online, in print, and via custom programs. Improving the effectiveness of healthcare through information and education, UBM Medica US provides unbiased clinical, practical, and business information for physicians, providers, payers, and patients around the world. Through journals, magazines, websites, online communities, drug databases, digital events, and other valuable resources, UBM Medica US also delivers comprehensive communication solutions for the pharmaceutical and related industries. Websites include CancerNetwork.com, ConsultantLive.com, DiagnosticImaging.com, MusculoskeletalNetwork.com, OBGYN.net, PhysiciansPractice.com, PsychiatricTimes.com and SearchMedica.com. UBM Medica US is part of UBM Connect – which provides marketing services across a number of communities, the largest of which are healthcare, medical device design and advanced manufacturing. UBM Connect also includes UBM Studios, the global leader in interactive digital environments. UBM Connect is a UBM plc company. For more information, visit http://www.UBMMedicaUS.com

Media contact:
Jason J. Golden
Content Marketing Manager
203-523-7040
jason.golden@ubm.com

 


'/>"/>
SOURCE UBM Medica US
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medical Device Developers - Network at BIOMEDevice Boston Next Week
2. Industry Veteran Brings Sales Expertise to AlloSources Growing Distribution Network
3. Blue Cross Blue Shield of Michigan and Blue Care Network support the Drug Enforcement Administrations Nationwide Prescription "Drug Take-Back Day"
4. RxAlly Expands National Network With Addition Of Nineteen Community Pharmacy Organizations Representing Over 2,000 Pharmacies
5. Mylan Sponsors Drug Store News and Pharmacist Society to Provide a New Business Networking Platform for Pharmacy Schools and Students
6. Medical Device Developers - Network at MD&M East Next Week
7. HIV Vaccine Trials Network Opens Enrollment for Phase 1 Trial of GeoVax Labs Second Generation HIV Vaccine
8. HealthWarehouse.com and Northwest Physicians Network Partner to Provide Exclusive Discount Pharmacy Services to Patients
9. Medical Oncology Association of Southern California Purchasing Network (MPN) Names Cardinal Health Specialty Solutions as its Primary Healthcare Solutions Partner
10. The MED Group Expands MED Suppliers Network to add Ventilator Program
11. RxAlly Member Pharmacies Invited To Become The Preferred Network For Smart Insurance Company Holdings, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 /PRNewswire/ ... ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic ... safety and tolerability profile of ropeginterferon alfa-2b versus HU ... the ongoing long-term follow-up trial CONTINUATION-PV to obtain European marketing ... to present this data to the FDA as it seeks ...
(Date:12/4/2016)... -- Sickle cell disease (SCD) is an inherited chronic ... get stuck in veins and block blood flow, which ... leading to death. Each year, approximately 300,000 people around ... them lack access to comprehensive care or effective treatment ... SCD, a pill called hydroxyurea approved more than a ...
(Date:12/2/2016)... SILVER SPRING, Md. , Dec. 2, 2016 /PRNewswire-USNewswire/ ... a new indication for Jardiance (empagliflozin) to reduce the ... 2 diabetes mellitus and cardiovascular disease. ... adults with type 2 diabetes mellitus," said Jean-Marc ... Metabolism and Endocrinology Products in FDA,s Center for Drug ...
Breaking Medicine Technology:
(Date:12/4/2016)... NY (PRWEB) , ... December 03, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – hosted its first Swirl: A Wine Tasting Event in New York City, ...
(Date:12/4/2016)... ... December 03, 2016 , ... Houston ... the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging Medicine ... Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, speakers, ...
(Date:12/4/2016)... (PRWEB) , ... December 04, 2016 , ... ... undergoing major cosmetic surgery can now take advantage of a cosmetic procedure known ... skin rejuvenation treatment that reduces the appearance of age spots, fine lines, ...
(Date:12/2/2016)... ... December 02, 2016 , ... Halfway through its partnership with ... preventative dental services to more than 15,900 children 5 years old and younger and ... $38 million over a span of five years to Western University of Health Sciences, ...
(Date:12/2/2016)... ... 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will host the ... the 2016 MPN Heroes—eight individuals who have made a difference in the field of ... standard of care, demonstrating leadership within the MPN community and/or a commitment to individual ...
Breaking Medicine News(10 mins):